Aarti Drugs Ltd. Share Price

Overview

Aarti Drugs Ltd. share price is currently ₹475.71, down by - ₹18.63 (3.77%) from its previous closing price of ₹494.34. The share price has gained 26.95% over the past month and gained 3.77% over the past year. The stock's 52-week low and high are ₹315.70 and ₹522.61, respectively. Aarti Drugs Ltd. has a market capitalisation of ₹ 4,422.49 Cr. The share price was last updated on 20 Nov 2026, 03:58 PM IST.

Aarti Drugs Ltd.
Aarti Drugs Ltd.
AARTIDRUGS
 ₹0.00
- ₹18.63
3.77%
Healthcare
 ₹0.00(%)1D

Updated: 20 Nov 2026, 03:58:27 pm IST

Market Data

Open Price

 ₹491.43

Prev. Close

 ₹494.34
 ₹472.44

Day Low

 ₹495.20

Day High

 ₹315.70

52 Week Low

 ₹522.61

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

18.98

Sector PE

46.21

PB Ratio

2.80

Sector PB

6.06

EPS

25.07

Dividend Yield

0.63

Today's Volume

290.719 K

5 Day Avg. Volume

328.340 K

PEG Ratio

1.19

Market Cap.

₹ 4,422.49 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsInterim Dividend of 20% at ₹2/Share
09-Feb-202609-Feb-2026
DividendsInterim Dividend of 10% at ₹1/Share
04-Feb-202504-Feb-2025

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
DSP Small Cap Fund - Regular Plan - Growth63.88 Lac
63.88 Lac
no change
ICICI Prudential Healthcare Fund - Growth18.56 Lac
16.32 Lac
(12.03%)
DSP Healthcare Fund - Regular Plan - Growth8.52 Lac
8.52 Lac
no change
Motilal Oswal BSE Healthcare ETF992
988
(0.4%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth468
473
(1.07%)

About Aarti Drugs Ltd. 👋

Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Stock Reader

Stock Reader

10 Nov • 9:09 PM · SEBI-Registered Analyst

AARTI DRUGS: A PHARMA BUSINESS REGAINING MOMENTUM 💊

AARTIDRUGS India’s pharmaceutical opportunity is not only about finished medicines. The companies manufacturing APIs, formulations and specialty chemicals are also positioned to benefit from global healthcare demand. Aarti Drugs is building its presence across all three. Aarti Drugs operates in Active Pharmaceutical Ingredients (APIs), formulations, specialty chemicals and intermediates, serving domestic and international pharmaceutical markets. And Q2 FY27 delivered a strong performance. Q2 FY27 consolidated results: Revenue: ₹829 crore, up 27% YoY. EBITDA: ₹138 crore, up 63% YoY. EBITDA margin: 16.6%, expanding 370 basis points. PAT: ₹82.8 crore, up 83% YoY. H1 FY27 revenue increased 23% to ₹1,532 crore, while EBITDA grew 48% to ₹235 crore. The interesting part is the improving business mix. API revenue grew 17% YoY to ₹605 crore. Formulations revenue increased 58% to ₹130 crore. Specialty chemicals revenue surged 92% to ₹72 crore. The company is also strengthening backward integration through its Sayakha facility, which is helping meet a significant share of its metformin intermediate requirements internally. The growth opportunity comes from: Rising demand for pharmaceutical ingredients. Expansion in regulated markets. Higher contribution from formulations. Backward integration and manufacturing efficiency. Better capacity utilisation. The business flywheel: API demand → Manufacturing scale → Backward integration → Better cost efficiency → Margin improvement. However, investors should not extrapolate the latest margins blindly. Management has acknowledged that strong pricing realisations contributed meaningfully to Q2 growth, and margins could normalise. Export performance, regulatory compliance, raw-material costs, capex execution and competition remain important risks.

See More
Palak Jain

Palak Jain

10 Nov • 4:56 PM · SEBI-Registered Analyst

Aarti Drugs Sees Strong Profit Growth In Q2

Sometimes, a small improvement in margins can make a big difference to a company's profitability. AARTIDRUGS delivered an encouraging performance in Q2 FY27, with growth in both revenue and profits. The interesting part is not just the increase in sales, but how the company manages its operating costs and profitability. Aarti Drugs operates in the pharmaceutical sector, manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. Its business is closely linked to demand from domestic and international pharmaceutical markets. For investors, there are a few things worth tracking here. First, whether the company can sustain its margin performance. Second, whether export demand continues to support growth. And third, how raw material costs and competition affect its profitability over the coming quarters. One strong quarter is encouraging, but consistency is what ultimately matters. I would keep an eye on the next set of results to understand whether this momentum is sustainable. Educational purpose only. Not investment advice.

See More
Threetrend Research

Threetrend Research

10 Nov • 12:21 PM · SEBI-Registered Analyst

That indicates a gradual shift in market sentiment

AARTIDRUGS A Rounding Bottom Pattern is a bullish reversal chart pattern that indicates a gradual shift in market sentiment from selling pressure to buying interest. It generally forms a U-shaped structure, where the price initially declines, enters a prolonged consolidation phase at the bottom, and then gradually starts recovering by forming higher lows. The concept behind this pattern is that selling pressure slowly weakens, while buyers begin accumulating the stock at lower levels. As the price moves towards the previous resistance zone, buying momentum gradually increases. A decisive breakout above the neckline or resistance zone, preferably supported by strong volume, confirms the rounding bottom breakout and may signal the beginning of a fresh uptrend. Traders should watch for a successful breakout and retest, as the previous resistance zone can subsequently act as a new support area.

See More
Manish Salvi

Manish Salvi

4 Nov • 4:32 PM · SEBI-Registered Analyst

Aarti Drugs erases 6.5% gain despite Q2 profit jump

Aarti Drugs shares hit an 11-month high on 4 Nov 2026 but closed 2.25% lower after Q2 profit rose 83.2%. Support is at 430 and resistance at 500. Aarti Drugs Limited [AARTIDRUGS] shares gained as much as 6.5% in morning trade on 4 November 2026 and touched an 11-month high. The gains faded before the close, and the stock ended the session 2.25% lower. The move followed Q2 consolidated results. Profit rose 83.2% year on year to Rs 82.9 crore, against Rs 45.3 crore. Revenue grew 26.6% to Rs 826.2 crore from Rs 652.8 crore. Profit grew faster than revenue, which points to stronger earnings growth in the quarter. A reversal from a high, on the day of strong results, shows buyers did not follow through. In my view, the fade from the high makes the setup cautious in the short term. Resistance sits at 500. A move above 500 would bring a continuation of the rally into focus. Support is at 430, and a fall below 430 would put a deeper pullback in view. Watch whether price holds above 430 in the next sessions and how it reacts near 500. Stance: cautious while price trades between 430 and 500. Disclaimer: I do not hold any position in this. This content is for informational purposes only and is not a recommendation to buy or sell. Investments in securities are subject to market risks. Please read all related documents carefully before investing.

See More
Bala Prasad Pal

Bala Prasad Pal

4 Nov • 9:25 AM · SEBI-Registered Analyst

Aarti Drugs rises as Q2 profit climbs 83.2%

Aarti Drugs gained over 6.5% on 4 November 2026 as Q2 profit rose 83.2%. Rs 535 is resistance, while Rs 450 remains the key support level today. Aarti Drugs Ltd. [ AARTIDRUGS ] rose more than 6.5% in morning trade on 4 November 2026. Its consolidated Q2 profit increased 83.2% year on year to Rs 82.9 crore from Rs 45.3 crore. Revenue grew 26.6% year on year to Rs 826.2 crore from Rs 652.8 crore. Profit grew faster than revenue, pointing to stronger earnings growth in the quarter. The share has rallied 34.7% from its 24 October 2026 low. The current price is 475, 12.6% from the Rs 535 resistance. Rs 450 is the stated support. In my view, short-term momentum remains bullish after the sharp advance, though the rally may pause or see profit-taking. A move above Rs 535 would bring further strength into focus. A fall below Rs 450 would weaken the bullish view and put the advance under pressure. Watch the price reaction near Rs 535 and whether Rs 450 holds on a decline. The current price and chart structure should be checked against the latest trading screen. Stance: bullish in the short term while above Rs 450, with Rs 450 as the key support. Disclaimer: I do not hold any position in this. This content is for informational purposes only and is not a recommendation to buy or sell. Investments in securities are subject to market risks. Please read all related documents carefully before investing.

See More
Amit Malviya

Amit Malviya

28 Oct • 10:37 AM · SEBI-Registered Analyst

Aarti Drugs posts 16% PAT growth, new MD takes charge

AARTIDRUGS Aarti Drugs Ltd has recently reported strong financial results with FY26 consolidated PAT rising 16% to ₹195 crore, alongside a leadership transition where Adhish P. Patil has taken over as Managing Director effective October 2026. The stock has shown bullish technical momentum, trading around ₹379–402 with recent gains of over 6%. 📊 Latest Financial Highlights FY26 Consolidated PAT: ₹195 crore, up 16% YoY from ₹168 crore. Revenue: ₹2,568 crore, up 6.8% YoY. EBITDA: ₹312 crore, despite margin pressures from start-up costs and geopolitical headwinds. Q1FY27 Revenue: ₹703.6 crore, up 19% YoY, driven by API price hikes and volume growth. Q1FY27 EBITDA: ₹96.9 crore, margins expanded to 13.8%. 🏢 Corporate & Management Updates Leadership Transition: Shri Prakash M. Patil retired as Chairman, MD & CEO on 30 Sept 2026. Adhish P. Patil promoted from CFO to MD effective 1 Oct 2026. Shri Rashesh C. Gogri appointed as Chairman. Performance Stock Option Plan (PSOP 2026): Approved at AGM with 84.8% shareholder support, though institutional investors voted 99.7% against. Up to 8 lakh performance stock options authorized. 📈 Stock Performance & Technicals Latest Price: Around ₹402.25 (NSE/BSE). Day Range: ₹380.85 – ₹404.80. 52-Week Range: ₹318.95 – ₹534.00. Recent Move: +6.04% on 27 Oct 2026. Technical Outlook: Momentum shifted from sideways to mildly bullish. Daily moving averages turning positive. Weekly MACD mildly bearish, monthly MACD mildly bullish (mixed signals). RSI neutral, suggesting room for directional movement. ⚠️ Risks & Watchpoints Geopolitical Risks: Raw material supply chain pressures, especially ammonia. Institutional Resistance: Strong opposition to PSOP 2026 may signal governance concerns. Market Volatility: Despite PAT growth, margins remain sensitive to raw material inflation.

See More

News & Events

Frequently Asked Questions

What is the share price of Aarti Drugs Ltd.?

What is the market cap of Aarti Drugs Ltd.?

Should I buy Aarti Drugs Ltd. stock now?

What is the 52 week high and low of Aarti Drugs Ltd.?

Is the Aarti Drugs Ltd. stock good to buy?

Is Aarti Drugs Ltd. a good buy for the long term?

Is Aarti Drugs Ltd. overvalued or undervalued?

What is the PE and PB ratio of Aarti Drugs Ltd.?

Start Now